Loading…
LEUCOVORIN CALCIUM is a brand name for Leucovorin, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: , 1.1 Pediatric, 1.2 Geriatrics 2025-05
Verbatim from this product's HC label. Tap a section to expand.
1. of the PM Guidance) or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. RECENT MAJOR LABEL CHANGES .............................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART 1: HEALTHCARE PROFESSIONAL INFORMATION ..............................................................
4 1 INDICATIONS ..................................................................................................................... 1 Pediatrics ..........................................................................................................................
2 Geriatrics .......................................................................................................................... 4 2 CONTRAINDICATIONS ........................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................. 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 2 Recommended Dose and Dosage Adjustment ...........................................................
3 Reconstitution ................................................................................................................. 4 Administration .................................................................................................................
7 5 OVERDOSE ......................................................................................................................... 7
). • Fatalities have occurred as a result of myelosuppression (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS). • Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), some fatal, have been reported in patients receiving leucovorin in combination therapy (see 8 ADVERSE REACTIONS).
• Leucovorin may diminish the effect of anti-epileptic substances such as phenobarbital, primidone and phenytoin. During leucovorin administration in epileptic patients treated with these substances, there is a risk to increase the frequency of seizures due to a decrease of plasma concentrations of anti-epileptic drugs (see
1. of the PM Guidance) or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. RECENT MAJOR LABEL CHANGES .............................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART 1: HEALTHCARE PROFESSIONAL INFORMATION ..............................................................
4 1 INDICATIONS ..................................................................................................................... 1 Pediatrics ..........................................................................................................................
2 Geriatrics .......................................................................................................................... 4 2 CONTRAINDICATIONS ........................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................. 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 2 Recommended Dose and Dosage Adjustment ...........................................................
3 Reconstitution ................................................................................................................. 4 Administration .................................................................................................................
7 5 OVERDOSE ......................................................................................................................... 7 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ....................................... 8 7 WARNINGS AND PRECAUTIONS ........................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Leucovorin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
8 General ....................................................................................................................................... 8 Gastrointestinal .........................................................................................................................
9 Monitoring and Laboratory Tests ......................................................................................... 10 Neurologic ................................................................................................................................
10 Reproductive Health ............................................................................................................... 1 Special Populations .......................................................................................................
1 Pregnancy ................................................................................................................ 2 Breast-feeding .........................................................................................................
3 Pediatrics ................................................................................................................. 4 Geriatrics..................................................................................................................
11 8 ADVERSE REACTIONS ....................................................................................................... 1 Adverse Reaction Overview .........................................................................................
2 Clinical Trial Adverse Reactions .................................................................................. 5 Post-Market Adverse Reactions ..................................................................................
12 9 DRUG INTERACTIONS ...................................................................................................... 1 Serious Drug Interactions ................................................................................................
4 Drug-Drug Interactions ................................................................................................. 5 Drug-Food Interactions ................................................................................................
6 Drug-Herb Interactions ................................................................................................ 7 Drug-Laboratory Test Interactions .............................................................................
14 10 CLINICAL PHARMACOLOGY .............................................................................................. 1 Mechanism of Action ....................................................................................................
2 Pharmacodynamics ....................................................................................................... 3 Pharmacokinetics ..........................................................................................................
15 11 STORAGE, STABILITY AND DISPOSAL ............................................................................... 16 PART 2: SCIENTIFIC INFORMATION ......................................................................................
17 13 PHARMACEUTICAL INFORMATION .................................................................................. 17 14 CLINICAL TRIALS...............................................................................................................
18 15 MICROBIOLOGY ............................................................................................................... 18 16 […]